Immune cells and allergic reactions to asparaginase in leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at why some patients have allergic reactions to asparaginase, a chemotherapy drug used to treat acute lymphoblastic leukemia. By studying blood samples taken before the consolidation phase, researchers hope to find ways to predict and manage these reactions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of acute lymphoblastic leukemia (ALL), based on standard tests.
- Your treatment plan must include asparaginase (a chemotherapy drug) as part of the standard protocol.
- You must be at least 1 year old.
- You must be enrolled before the consolidation phase, meaning you're still in the induction phase or earlier.
- You must not have had a prior stem cell (bone marrow) transplant.
- You must not have Down syndrome, because that affects how the body handles the drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how the immune system (T cells and B cells) responds to a common chemotherapy drug called asparaginase. It aims to understand why some children develop antibodies against the drug, which may cause allergic reactions and reduce effectiveness, to help improve future treatments.
This study looks at how a common chemotherapy drug called asparaginase affects people in real life. It aims to understand side effects better so doctors can improve care for patients with leukemia or lymphoma.
This trial looks at how a medicine called asparaginase affects blood clotting in children treated for acute lymphoblastic leukaemia (a type of blood cancer). It may help doctors better manage bleeding or clot risks during treatment.
This trial tests adding an asparaginase drug to standard chemotherapy for adults with newly diagnosed acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL). The goal is to see if this combination improves outcomes.
This study looks at why some people develop liver problems while taking asparaginase, a common medicine used to treat newly diagnosed acute lymphoblastic leukemia (ALL). The goal is to use genetic information to better understand and potentially prevent this side effect.
This study looks at how many children develop high ammonia levels after receiving a cancer medicine called recombinant Erwinia asparaginase. It helps doctors understand side effects and keep patients safe.
Hear when a new Acute Lymphoblastic Leukemia ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.